SG10201506608RA - 3-deazaneplanocin derivatives - Google Patents

3-deazaneplanocin derivatives

Info

Publication number
SG10201506608RA
SG10201506608RA SG10201506608RA SG10201506608RA SG10201506608RA SG 10201506608R A SG10201506608R A SG 10201506608RA SG 10201506608R A SG10201506608R A SG 10201506608RA SG 10201506608R A SG10201506608R A SG 10201506608RA SG 10201506608R A SG10201506608R A SG 10201506608RA
Authority
SG
Singapore
Prior art keywords
deazaneplanocin
derivatives
deazaneplanocin derivatives
Prior art date
Application number
SG10201506608RA
Inventor
Christina L L Chai
Eric K W Tam
Haiyan Yang
Qiang Yu
Tuan Minh Nguyen
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Publication of SG10201506608RA publication Critical patent/SG10201506608RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201506608RA 2008-09-26 2009-09-25 3-deazaneplanocin derivatives SG10201506608RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10029108P 2008-09-26 2008-09-26

Publications (1)

Publication Number Publication Date
SG10201506608RA true SG10201506608RA (en) 2015-09-29

Family

ID=42059968

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201506608RA SG10201506608RA (en) 2008-09-26 2009-09-25 3-deazaneplanocin derivatives

Country Status (6)

Country Link
US (1) US20110237606A1 (en)
EP (1) EP2331543A4 (en)
JP (2) JP2012503651A (en)
CN (2) CN102369204A (en)
SG (1) SG10201506608RA (en)
WO (1) WO2010036213A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010027935A1 (en) 2008-09-08 2010-03-11 Merck Sharp & Dohme Corp. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
US8846935B2 (en) 2010-05-07 2014-09-30 Glaxosmithkline Llc Indazoles
BR112012028556A2 (en) 2010-05-07 2014-04-01 Glaxosmithkline Llc INDOS
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
JP5908493B2 (en) * 2010-12-01 2016-04-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Indole
AU2012332297B2 (en) 2011-11-04 2016-01-07 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
CN104136020B (en) 2012-02-27 2018-08-28 不列颠哥伦比亚癌症局分支机构 Effect protein interaction is reprogrammed to correct the epigenetic defect in cancer
WO2013173635A1 (en) * 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
JP2015518713A (en) 2012-05-16 2015-07-06 ラナ セラピューティクス インコーポレイテッド Compositions and methods for modulating UTRN expression
WO2013173637A1 (en) * 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
EP2850188A4 (en) 2012-05-16 2016-01-20 Rana Therapeutics Inc Compositions and methods for modulating hemoglobin gene family expression
CA2873794A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating smn gene family expression
WO2013173598A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating atp2a2 expression
EA201492116A1 (en) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF MECP2
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
EP2914254B1 (en) * 2012-10-30 2020-01-08 MEI Pharma, Inc. Combination therapies to treat chemoresistant cancers
WO2016022563A1 (en) * 2014-08-04 2016-02-11 Auburn University Enantiomers of the 1',6'-isomer of neplanocin a
CA2966044A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
PE20211444A1 (en) * 2017-12-13 2021-08-05 Lupin Ltd BICYCLE HETEROCYCLIC COMPONENTS REPLACED AS PRMT5 INHIBITORS
EP3545756A1 (en) 2018-03-28 2019-10-02 KWS SAAT SE & Co. KGaA Regeneration of plants in the presence of inhibitors of the histone methyltransferase ezh2
US20230302003A1 (en) * 2020-08-06 2023-09-28 Antirna Incorporated Compositions and methods for treating a coronavirus infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3148363A1 (en) * 1980-12-12 1982-09-16 Toyo Jozo K.K., Shizuoka NEPLANOCIN A DERIVATIVES
US4968690A (en) * 1986-05-27 1990-11-06 United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
EP0277599A3 (en) * 1987-01-30 1990-05-09 Asahi Glass Company Ltd. Fluorine containing cyclopentane derivatives and processes for their production
ZA894534B (en) * 1988-06-20 1990-03-28 Merrell Dow Pharma Novel neplanocin derivatives
JPH02215781A (en) * 1989-02-14 1990-08-28 Toyo Jozo Co Ltd 6'-deoxy-6'-halogenoneplanocin a and production thereof
GB8926417D0 (en) * 1989-11-22 1990-01-10 Wellcome Found Heterocyclic compounds
US5514688A (en) * 1990-09-14 1996-05-07 Merrell Dow Pharmaceuticals Inc. Carbocyclic adenosine analogs useful as immunosuppressants
US5817672A (en) * 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
WO1994018971A1 (en) * 1993-02-19 1994-09-01 Southern Research Institute D-carbocyclic-3-deazaadenosine analogues and their use as antiviral agents
EP1221615A2 (en) * 1995-04-25 2002-07-10 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US6475985B1 (en) * 1998-03-27 2002-11-05 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
CZ294538B6 (en) * 2002-12-30 2005-01-12 Ústav Experimentální Botaniky Akademie Vědčeské Re Substituting derivatives of N6-benzyladenosine, process of their preparation, their use in the preparation of medicaments, cosmetic compositions and growth regulators, as well as pharmaceutical preparations, cosmetic compositions and growth regulators in which these compounds are comprised
PT1848718E (en) * 2005-02-04 2012-10-11 Millennium Pharm Inc Inhibitors of e1 activating enzymes
EP2402334B1 (en) * 2006-02-02 2016-06-29 Millennium Pharmaceuticals, Inc. Inhibitors of E1 Activating Enzymes
EP1993553B1 (en) * 2006-03-02 2013-05-08 Agency for Science, Technology and Research Methods for cancer therapy and stem cell modulation
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer

Also Published As

Publication number Publication date
EP2331543A1 (en) 2011-06-15
WO2010036213A1 (en) 2010-04-01
EP2331543A4 (en) 2013-06-19
JP2012503651A (en) 2012-02-09
US20110237606A1 (en) 2011-09-29
JP2015007140A (en) 2015-01-15
CN104557914A (en) 2015-04-29
CN102369204A (en) 2012-03-07

Similar Documents

Publication Publication Date Title
HK1256310A1 (en) N-sulphonylpyrrole derivatives
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
EP2376494A4 (en) Dihydropyrimidopyrimidine derivatives
ZA201100799B (en) Imidazopyridin-2-one derivatives
SG10201506608RA (en) 3-deazaneplanocin derivatives
ZA201100876B (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
EP2291078A4 (en) Oxazolobenzimidazole derivatives
ZA201102449B (en) Morpholinopurine derivatives
EP2376493A4 (en) Dihydropyrimidopyrimidine derivative
EP2380877A4 (en) Pyridine-3-carboxyamide derivative
EP2279532A4 (en) Oxazolobenzimidazole derivatives
EP2269993A4 (en) 2-aminoquinazoline derivative
IL210869A0 (en) Imidazothiadiazoles derivatives
IL208336A0 (en) Pyrisazinone derivatives
IL206875A0 (en) Bicycloamine derivative
ZA201100948B (en) Acylaminobenzamide derivatives
IL211290A0 (en) New 2-amidothiadiazole derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
ZA201105050B (en) Quinazolinamide derivatives
EP2292613A4 (en) Dihydroindolinone derivatives
EP2258697A4 (en) Hydroxyquinoxalinecarboxamide derivative
EP2248811A4 (en) 2-oxochromene derivative